

Global Markets for Generic Drugs

<https://marketpublishers.com/r/G0D2B77CE3CEN.html>

Date: January 2024

Pages: 126

Price: US\$ 5,500.00 (Single User License)

ID: G0D2B77CE3CEN

Abstracts

Report Scope:

The report discusses the current size and growth of the market for generic drugs, both in global terms and broken down by the most important national markets. The report covers small molecule drugs and biosimilars. It includes market drivers and challenges in the generic drug industry. The competitive landscape includes generic drug sales of key competitors and their ranking in the market. It also covers the emerging trends in the generic drugs industry.

By geographical region, the market has been segregated into North America, Europe, Asia-Pacific, and the Rest of the World. The North America region includes countries such as the U.S., Canada and Mexico; Europe includes Germany, U.K., Italy, and Rest of Europe; Asia-Pacific includes China, India, Japan, and Rest of Asia-Pacific. The estimated values used are based on drug manufacturers' total revenues.

Report Includes:

37 data tables and 39 additional tables

An overview of the global markets for generic (pharmaceutical) drugs

Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028

Estimate of the market size and revenue forecast of the market for generic drugs, and corresponding market share analysis based on molecule type and geographic region

Evaluation of the current and future market potential of generic drugs, as well as the major generics, regulatory landscape and patent cliff within the biopharmaceutical industry

Discussion of the major market drivers, opportunities and challenges, emerging technologies, and regulations

Data and market value analyses for the U.S., Canada, Mexico, Germany, the U.K., Italy, China, India and Japan

Overview of the sustainability trends and factors in the market for generic drugs, with emphasis on consumer attitudes, ESG scores, case studies and the ESG practices of leading companies

Analysis of the pipeline for new generic drugs and their impact on the growth of the overall biopharmaceutical products market

Patent review and analysis of key patent grants

An analysis of the industry structure, including company market shares, recent M&A activity, and venture funding

Analysis of the top market players, their global rankings, recent developments, key financials and segmental revenues, and product portfolios

Profiles of the leading market players

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What's New in this Update?
Research Methodology
Information Sources
Regional Breakdown
Segmentation Breakdown

CHAPTER 2 SUMMARY AND HIGHLIGHTS

Market Outlook
Market Summary

CHAPTER 3 MARKET OVERVIEW

Introduction
Adequate Market Size
Patent-Expired Therapies
Older Products Still Used
Long-Term Use
Straightforward Production Technology
Drugs Used in Primary Care
Biosimilars

CHAPTER 4 MARKET DYNAMICS

Market Drivers
Increasing Patent Cliffs and Loss of Exclusivities
Favorable Healthcare Policies
Changing Physician Attitudes
Market Challenges
Pricing Pressures and Low Profit Margins
Patent Extension Strategies of Innovator Companies

CHAPTER 5 MARKET BREAKDOWN BY MOLECULE TYPE

Global Market for Generic Drugs
Global Generic Drugs Market, by Molecule Type
Small Molecule Generics
Biosimilars

CHAPTER 6 MARKET BREAKDOWN BY REGION

Introduction
North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific
Rest of the World

CHAPTER 7 SUSTAINABILITY: AN ESG PERSPECTIVE

Introduction to ESG
Sustainability in the Generic Drugs Industry: An ESG Perspective
Key ESG Issues
Environmental Performance of Key Generic Drug Companies
Social Performance of Key Generic Drug Companies
Governance Performance of Key Generic Drug Companies
Case Study
Concluding Remarks from BCC

CHAPTER 8 EMERGING TRENDS AND DEVELOPMENTS

Key Trends in the Market
Collaborations for R&D
Rise of Complex Generics in Immunology and Oncology
Improving Portfolio Efficiency
Focus on Emerging Markets

CHAPTER 9 REGULATORY LANDSCAPE

Regulatory Overview
U.S.
Evolving Situation in the U.S.
European Union
Japan
Regulation of Biosimilars
EU Provisions
Authorized Generic Drugs

CHAPTER 10 COMPETITIVE LANDSCAPE

Competitive Landscape
M&A Analysis

CHAPTER 11 COMPANY PROFILES

ASPEN PHARMACARE
AUROBINDO PHARMA
CIPLA INC.
DR. REDDY'S LABORATORIES LTD.
FRESENIUS KABI
LUPIN LTD.
SANDOZ
SUN PHARMACEUTICAL INDUSTRIES LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
VIATRIS INC.

List Of Tables

LIST OF TABLES

- Summary Table A : Global Market for Generic Drugs, by Molecule Type, Through 2028
- Summary Table B : Global Market for Generic Drugs, by Region, Through 2028
- Table 1 : List of Block Buster Drugs Undergoing Patent Expiry in Coming Years
- Table 2 : Global Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
- Table 3 : Global Market for Generic Drugs, by Top 10 Countries, Through 2028
- Table 4 : Global Top Selling Pharmaceuticals, 2022
- Table 5 : Global Market for Generic Drugs, by Molecule Type, Through 2028
- Table 6 : Global Market for Small Molecule Generics, by Region, Through 2028
- Table 7 : Approved Biosimilar Products in the U.S.
- Table 8 : Global Market for Biosimilars, by Region, Through 2028
- Table 9 : Global Market for Generic Drugs, by Region, Through 2028
- Table 10 : North American Market for Generic Drugs, Through 2028
- Table 11 : U.S. Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
- Table 12 : Canadian Key Therapeutic Areas in Retail and Hospital Purchases, 2022
- Table 13 : Canadian Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
- Table 14 : European Market for Generic Drugs, by Country, Through 2028
- Table 15 : German Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
- Table 16 : French Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
- Table 17 : Italian Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
- Table 18 : U.K. Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
- Table 19 : Spanish Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
- Table 20 : Penetration of Generic Drugs in the Pharmaceutical Market in Other European Countries, 2022
- Table 21 : Rest of the European Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
- Table 22 : Asia-Pacific Market for Generic Drugs, by Country, Through 2028
- Table 23 : Chinese Market for Generic Drugs Compared with the Total Pharmaceutical

Market, Through 2028

Table 24 : Japanese Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028

Table 25 : Indian Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028

Table 26 : Rest of Asia-Pacific Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028

Table 27 : RoW Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028

Table 28 : ESG Rankings for Major Generic Drugs Companies, 2023*

Table 29 : ESG: Environmental Overview

Table 30 : ESG: Social Overview

Table 31 : ESG: Governance Overview

Table 32 : Teva: ESG Ratings Received, 2022

Table 33 : Collaborations for R&D and Licensing Agreements, 2022 and 2023

Table 34 : Portfolio Expansion Activities of Key Generic Companies

Table 35 : Requirements for NDA and ANDA Applications

Table 36 : Leading Generic Drug Companies, by Sales, 2022

Table 37 : Comparative Analysis of Top Three Competitors

Table 38 : M&A Analysis of Generic Drugs Markets, 2022 and 2023

Table 39 : Aspen Pharmacare Holdings Ltd.: Company Snapshot

Table 40 : Aspen Pharmacare Holdings Ltd.: Financials, 2021 and 2022

Table 41 : Aspen Pharmacare Holdings Ltd: Key Product Portfolio

Table 42 : Aspen Pharmacare Holdings Ltd.: Recent Developments, 2023

Table 43 : Aurobindo Pharma Ltd.: Company Snapshot

Table 44 : Aurobindo Pharma Ltd.: Financials, 2021 and 2022

Table 45 : Aurobindo Pharma Ltd.: Recent Developments, 2022

Table 46 : Cipla Inc.: Company Snapshot

Table 47 : Cipla Inc.: Financials, 2021 and 2022

Table 48 : Cipla Inc.: Key Product Launches, by Region, 2022

Table 49 : Cipla Inc.: Recent Developments, 2023

Table 50 : Dr. Reddy's Laboratories Ltd.: Company Snapshot

Table 51 : Dr. Reddy's Laboratories Ltd.: Financials, 2021 and 2022

Table 52 : Dr. Reddy's Laboratories Ltd.: Biosimilars Portfolio

Table 53 : Dr. Reddy's Laboratories Ltd.: Recent Developments, 2022-2023

Table 54 : Fresenius Kabi AG: Company Snapshot

Table 55 : Fresenius Kabi AG: Biosimilars Portfolio

Table 56 : Fresenius Kabi AG: Biosimilar Products in Pipeline

Table 57 : Fresenius Kabi AG: Recent Developments, 2022-2023

- Table 58 : Lupin Ltd.: Company Snapshot
- Table 59 : Lupin Ltd.: Financials, 2021 and 2022
- Table 60 : Lupin Ltd.: Recent Developments, 2023
- Table 61 : Sandoz Group AG: Company Snapshot
- Table 62 : Sandoz Group AG: Financials, 2021 and 2022
- Table 63 : Sandoz Group AG: Product Portfolio
- Table 64 : Sandoz Group AG: Key Biosimilar Products in Phase III and Registration
- Table 65 : Sandoz Group AG: Recent Developments, 2023
- Table 66 : Sun Pharmaceutical Industrial Ltd.: Company Snapshot
- Table 67 : Sun Pharmaceutical Industrial Ltd.: Financials, 2021 and 2022
- Table 68 : Teva Pharmaceutical Industrial Ltd.: Company Snapshot
- Table 69 : Teva Pharmaceutical Industrial Ltd.: Financials, 2021 and 2022
- Table 70 : Teva Pharmaceutical Industrial Ltd.: Biosimilars Portfolio
- Table 71 : Teva Pharmaceutical Industrial Ltd.: Recent Developments, 2023
- Table 72 : Viatris Inc.: Company Snapshot
- Table 73 : Viatris Inc.: Financials, 2021 and 2022
- Table 74 : Viatris Inc.: Recent Developments, 2022-2023

List Of Figures

LIST OF FIGURES

Summary Figure A : Global Market for Generic Drugs, by Molecule Type, 2020-2028

Summary Figure B : Global Market for Generic Drugs, by Region, 2020-2028

Figure 1 : Generic Drugs Market Dynamics

Figure 2 : Generic Drugs Approved in the U.S., 2019-2022

Figure 3 : Regulatory Pathways for Small Molecule Generics and Biosimilars

Figure 4 : Global Market Shares of Generic Drugs, by Molecule Type, 2022

Figure 5 : Global Market for Small Molecule Generics, 2020-2028

Figure 6 : Global Market for Biosimilars, 2020-2028

Figure 7 : Snapshot of Global Market for Generic Drugs, by Region

Figure 8 : Global Market Shares of Generic Drugs, by Region, 2022

Figure 9 : Annual Savings from Biosimilars and Generics in the U.S., 2019-2022

Figure 10 : European Market Shares of Generic Drugs, by Country, 2022

Figure 11 : Asia-Pacific Market Shares of Generic Drugs, by Country, 2022

Figure 12 : ESG Pillars

Figure 13 : Advantages of ESG for Companies in the Generic Drugs Market

Figure 14 : Key Focus Areas in ESG Metrics in the Generics Market

Figure 15 : Teva: ESG Indicators, 2022

Figure 16 : Emerging Trends in the Generic Drugs Market

Figure 17 : Aspen Pharmacare Holdings Ltd.: Financials, 2021 and 2022

Figure 18 : Aspen Pharmacare Holdings Ltd.: Market Share, by Business Segment, 2022

Figure 19 : Aspen Pharmacare Holdings Ltd.: Revenue Share, by Region, 2022

Figure 20 : Aurobindo Pharma Ltd.: Financials, 2021 and 2022

Figure 21 : Aurobindo Pharma Ltd.: Revenue Share, by Business Segment, 2022

Figure 22 : Aurobindo Pharma Ltd.: ANDA Filings, by Region, FY2022

Figure 23 : Cipla Inc.: Financials, 2021 and 2022

Figure 24 : Cipla Inc.: Revenue Share, by Business Segment, 2022

Figure 25 : Cipla Inc.: ANDAs Pipeline, FY 2022

Figure 26 : Dr. Reddy's Laboratories Ltd.: Financials, 2021 and 2022

Figure 27 : Dr. Reddy's Laboratories Ltd.: Revenue Share, by Business Segment, 2022

Figure 28 : Dr. Reddy's Laboratories Ltd.: Global Generics Revenue Share, by Therapeutic Area, 2022

Figure 29 : Dr. Reddy's Laboratories Ltd.: Revenue Share, by Country, 2022

Figure 30 : Lupin Ltd.: Financials, 2021 and 2022

Figure 31 : Lupin Ltd.: Revenue Share, by Business Segment, 2022

Figure 32 : Lupin Ltd.: India Revenue Share, by Therapeutic Area, 2022

Figure 33 : Timeline of Novartis and Sandoz Separation

Figure 34 : Sandoz Group AG: Financials, 2021 and 2022

Figure 35 : Sandoz Group AG: Market Share, by Business Segment, 2022

Figure 36 : Sandoz Group AG: Revenue Share, by Region, 2022

Figure 37 : Sun Pharmaceutical Industrial Ltd.: Financials, 2021 and 2022

Figure 38 : Sun Pharmaceutical Industrial Ltd.: Revenue Share, by Business Segment, 2022

Figure 39 : Cumulative ANDAs Filed and Approved in the U.S., FY 2019-FY 2023

Figure 40 : Teva Pharmaceutical Industrial Ltd.: Financials, 2021 and 2022

Figure 41 : Teva Pharmaceutical Industrial Ltd.: Revenue Share, by Region, 2022

Figure 42 : Viatris Inc.: Financials, 2021 and 2022

Figure 43 : Viatris Inc.: Market Share, by Business Segment, 2022

Figure 44 : Viatris Inc.: Revenue Share, by Region, 2022

I would like to order

Product name: Global Markets for Generic Drugs

Product link: <https://marketpublishers.com/r/G0D2B77CE3CEN.html>

Price: US\$ 5,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0D2B77CE3CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970